Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Prevnar 20, Pfizer Aims To Maintain A Top Franchise

Executive Summary

The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.

You may also be interested in...



Merck, Pfizer Pneumococcal Vaccines: More Serotype Protection Vs. Pneumonia Indication

Ahead of CDC advisory committee this fall, Merck highlights additional bacteria serotypes its Vaxneuvance protects against while Pfizer touts Prevnar 13’s indication for pneumonia.

Affinivax's 24-Valent Pneumococcal Vaccine Targets Growing And Changing Market

A potential next-generation, 24-valent, pneumococcal vaccine in development by Affinivax and Astellas has shown strong immunogenicity in a Phase II study and is preparing to enter pivotal Phase III trials; if successful, it will target a growing market currently dominated by big pharma players.

Pfizer’s Prevnar 20 May Have Edge Over Merck’s Pneumococcal Vaccine, ACIP Suggests

CDC advisory committee work group concludes benefits of Merck’s PVC15 in those 65 and older is small while benefits of Pfizer’s PVC20 in those 50 and older is large and in those 65 and older is moderate to large.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel